The Johns Hopkins-led and NIH funded OUtMATCH study led to the development of Xolair, a groundbreaking drug that reduces the ...

The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

Among adults with chronic rhinosinusitis with nasal polyps who endured endoscopic sinus surgery, those with severe vs. mild ...

Joseph spent his childhood dreading family gatherings. His Egyptian-American relatives would gather around the family table ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

Zeit Aktuelle Nachrichten 17:34 Sanofi EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first ...

French pharma major Sanofi and US partner Regeneron Pharmaceuticals yesterday presented positive results from the EVEREST ...

As seasons change, temperatures rise and flowers begin to bloom, many find themselves battling more than just spring fever, ...

Alvotech and Advanz Pharma have inked a deal to expand their commercial partnership to cover three additional biosimilar ...

The latest update atopic dermatitis guidelines include the new approval of lebrikizumab and the expanded use of baricitinib ...

Since the European Medicines Agency (EMA) approval of omalizumab in 2005 as the first ever biologic for severe asthma, the respiratory community has seen a continuous growth in the number of biologics ...

Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab ...